NCT00005875已完成2 期
Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic melanoma.
详细描述
OBJECTIVES: I. Assess the efficacy and toxicity of nitrocamptothecin in patients with metastatic melanoma.
OUTLINE: Patients are stratified according to disease (choroidal vs nonchoroidal). Patients receive oral nitrocamptothecin daily on days 1-5. Treatment continues weekly for at least 8 weeks (2 courses) in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 28-74 patients (14-37 per stratum) will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast CancerBreast CancerNCT00005873Astex Pharmaceuticals, Inc.
已完成
2 期
Nitrocamptothecin in Treating Patients With Soft Tissue SarcomasSmall Intestine CancerSarcomaGastrointestinal Stromal TumorNCT00005874Astex Pharmaceuticals, Inc.
Unknown
3 期
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic CancerPancreatic CancerNCT00005871Astex Pharmaceuticals, Inc.
Unknown
3 期
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT00005869Astex Pharmaceuticals, Inc.
Unknown
3 期
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the PancreasPancreatic CancerNCT00005870Astex Pharmaceuticals, Inc.